BIO-RAD LABORATORIES, INC.BIOEarnings & Financial Report
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets. The company was founded in 1952 in Berkeley, California, by husband and wife team David and Alice Schwartz, both graduates of the University of California, Berkeley. Bio-Rad is based in Hercules, California, and has operations worldwide.
BIO Q4 2025 Key Financial Metrics
Revenue
$693.2M
Gross Profit
$345.2M
Operating Profit
$-118.9M
Net Profit
$720.0M
Gross Margin
49.8%
Operating Margin
-17.2%
Net Margin
103.9%
YoY Growth
3.9%
EPS
$26.59
Financial Flow
BIO-RAD LABORATORIES, INC. Q4 2025 Financial Summary
BIO-RAD LABORATORIES, INC. reported revenue of $693.2M for Q4 2025, with a net profit of $720.0M (103.9% margin). Cost of goods sold was $348.0M, operating expenses totaled $464.1M.
Key Financial Metrics
| Total Revenue | $693.2M |
|---|---|
| Net Profit | $720.0M |
| Gross Margin | 49.8% |
| Operating Margin | -17.2% |
| Report Period | Q4 2025 |
BIO-RAD LABORATORIES, INC. Annual Revenue by Year
BIO-RAD LABORATORIES, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $2.6B).
| Year | Annual Revenue |
|---|---|
| 2025 | $2.6B |
| 2024 | $2.6B |
| 2023 | $2.7B |
| 2022 | $2.8B |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $610.8M | $638.5M | $649.7M | $667.5M | $585.4M | $651.6M | $653.0M | $693.2M |
| YoY Growth | -9.8% | -6.3% | 2.8% | -2.0% | -4.2% | 2.1% | 0.5% | 3.9% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $12.61B | $9.69B | $10.60B | $9.36B | $9.53B | $10.21B | $9.70B | $10.58B |
| Liabilities | $3.56B | $2.91B | $3.12B | $2.79B | $2.85B | $3.09B | $2.96B | $3.12B |
| Equity | $9.05B | $6.78B | $7.49B | $6.57B | $6.68B | $7.13B | $6.74B | $7.45B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $69.8M | $97.6M | $163.6M | $124.2M | $129.9M | $116.5M | $120.9M | $164.9M |
More Companies
ILMN
ILLUMINA, INC.
Revenue
$1.2B
Net Profit
$334.0M
UTHR
UNITED THERAPEUTICS Corp
Revenue
$799.5M
Net Profit
$338.7M
GMAB
GENMAB A/S
Revenue
$925.0M
Net Profit
$336.0M
GH
Guardant Health, Inc.
Revenue
$265.2M
Net Profit
$-92.7M
NBIX
NEUROCRINE BIOSCIENCES INC
Revenue
$805.5M
Net Profit
$153.7M
EXEL
EXELIXIS, INC.
Revenue
$598.7M
Net Profit
$244.5M
MDGL
MADRIGAL PHARMACEUTICALS, INC.
Revenue
$287.3M
Net Profit
$-114.2M
QGEN
QIAGEN N.V.
BMRN
BIOMARIN PHARMACEUTICAL INC
Revenue
$776.1M
Net Profit
$-30.7M
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Revenue
$264.0M
Net Profit
$30.8M